PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

🧠 Clinical library

Clinical Specialty Index

538 articles indexed across 24 specialties, each reviewed by a licensed pharmacist before publication.

Showing 23 from 1 topic.Sort: Newest | Oldest
Calcineurin Inhibitor Triple Therapy Ranks Highest for Lupus Nephritis Remission
Analysis Rheumatology / Immunology Confirmatory Grade: Moderate
Contreras G, Mechery V, Kota S, et al.
Aug 5, 2026 · Published in: Lupus

Triple therapy with Tacrolimus or Voclosporin excels in lupus nephritis remission.

Interferon and TYK2 blockade improve cutaneous lupus activity
Analysis Rheumatology / Immunology Hypothesis-generating Grade: Low
Candia González DA, Dávila Vargas D, Arango Machado V, et al.
Jul 29, 2026 · Published in: Dermatology Online Journal

Targeted therapies show promise in cutaneous lupus erythematosus treatment.

Continuing upadacitinib beats withdrawal for giant cell arteritis remission
Analysis Rheumatology / Immunology Practice-changing Grade: Moderate
Schmidt WA, Setty AR, Dejaco C, et al.
Jul 28, 2026 · Published in: Annals of the Rheumatic Diseases

Upadacitinib maintains better remission in long-term GCA treatment.

Oral JAK Inhibitors Drive Time-Dependent Regrowth in Adolescent-Inclusive Alopecia Areata
Analysis Rheumatology / Immunology Confirmatory Grade: Moderate
Morriss S, Foo CH, Lin E, et al.
Jul 28, 2026 · Published in: American Journal of Clinical Dermatology
Also in Pediatrics

JAK inhibitors boost hair regrowth in alopecia areata sufferers.

Dupilumab After JAK Inhibitor Withdrawal: Small Real-World Signal
Analysis Rheumatology / Immunology Hypothesis-generating Grade: Very Low
Wang Q, Yang G, Li Y, et al.
Jul 16, 2026 · Published in: Frontiers in Immunology

Switching from JAK inhibitors to dupilumab shows promise in atopic dermatitis management.

JAK Inhibitors Show Limited Efficacy in Refractory JIA Uveitis
Analysis Rheumatology / Immunology Hypothesis-generating Grade: Very Low
Baquet-Walscheid K, Wortmann C, Rothaus K, et al.
Jul 11, 2026 · Published in: Pediatric Rheumatology Online Journal

Janus kinase inhibitors show limited efficacy in JIA-associated uveitis.

2025 ACR SLE Guideline Prioritizes Hydroxychloroquine and Glucocorticoid Minimization
Guideline Rheumatology / Immunology Practice-changing Grade: Low
Sammaritano LR, Askanase A, Bermas BL, et al.
Jul 4, 2026 · Published in: Arthritis & Rheumatology (Hoboken, N.J.)

New guidelines unify SLE treatment strategies for better outcomes.

Obinutuzumab Improves Response in Active Non-Renal SLE
Analysis Rheumatology / Immunology Practice-changing Grade: High
Furie RA, Dall'Era M, Vital EM, et al.
Mar 6, 2026 · Published in: N Engl J Med

Obinutuzumab improves SLE outcomes in the recent ALLEGORY trial.